Repositioning Candidate Details
| Candidate ID: | R0397 |
| Source ID: | DB01618 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Molindone |
| Synonyms: | |
| Molecular Formula: | C16H24N2O2 |
| SMILES: | CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2 |
| Structure: |
|
| DrugBank Description: | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to moderate affinity for cholinergic and alpha-adrenergic receptors. Some electrophysiologic data from animals indicate that molindone has certain characteristics that resemble those of clozapine. (From AMA Drug Evaluations Annual, 1994, p283) |
| CAS Number: | 7416-34-4 |
| Molecular Weight: | 276.374 |
| DrugBank Indication: | Molindone is used for the management of the manifestations of psychotic disorders. |
| DrugBank Pharmacology: | Molindone is a dihydroindolone compound which is not structurally related to the phenothiazines, the butyrophenones, or the thioxanthenes. Molindone has a pharmacological profile in laboratory animals which predominantly resembles that of major tranquilizers causing reduction of spontaneous locomotion and aggressiveness, suppression of a conditioned response and antagonism of the bizarre stereotyped behavior and hyperactivity induced by amphetamines. In addition, molindone antagonizes the depression caused by the tranquilizing agent tetrabenazine. |
| DrugBank MoA: | The exact mechanism has not been established, however, based on electroencephalogram (EEG) studies, molindone is thought to act by occupying (antagonizing) dopamine (D2) receptor sites in the reticular limbic systems in the brain, thus decreasing dopamine activity. Decreased dopamine activity results in decreased physiological effects normally induced by excessive dopamine stimulation, such as those typically seen in manifestations of psychotic disorders. |
| Targets: | Dopamine D2 receptor; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A; Muscarinic acetylcholine receptor M1 |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|